{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".831","upperLimit":".901","value":"87.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"498"}],"units":"Participants"}],"description":"EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate.","groups":[{"description":"Total therapy applies to all eligible patients.","id":"OG000","title":"Total Therapy"}],"paramType":"NUMBER","populationDescription":"498 enrolled patients were eligible for analysis to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy.","reportingStatus":"POSTED","timeFrame":"Median follow-up time (range) 5.6 (1.3 to 8.9) years","title":"Overall Event-free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}